BioAlliance Pharma expands and strengthens its industrial property assets with two patent grants
Paris, July 10, 2013 - BioAlliance Pharma SA (Euronext Paris - BIO), an innovative Company dedicated to the development of orphan oncology products and supportive care products, announces it was granted two patents by the American and Japanese Offices protecting two of its products; Oravig® (miconazole for the treatment of oropharyngeal candidiasis) and Sitavig® (acyclovir for the treatment of labial herpes).
With these two new patents, BioAlliance Pharmas patent portfolio consists of 19 families of published patents, including 285 patents and patent applications for technologies or innovative products. More than 70 % of the portfolio is composed of patents providing long-term protection for the products.
The industrial property is a key asset for BioAlliance and lies at the core of the Companys growth strategy. The reinforcement and the territory expansion of our patents allow to ensure the largest and longest possible protection, optimizing our programs value. One such example is the grant of these two new patents, declared Judith Greciet, CEO of BioAlliance Pharma.
New protection of Sitavig® in Japan
In addition to the first Japanese patent protecting the mucoadhesive tablet, and further to the patent protections obtained for Europe, the US and China, this grant is the first one specific to Sitavig® in Japan for the treatment of labial herpes.
New protection of Oravig® in the US
The American patent office announced its decision to deliver a new grant covering Oravig®, a miconazole mucoadhesive tablet for the treatment of oropharyngeal candidiasis. This new patent enables BioAlliance to expand the scope of protection already given by two US patents protecting Oravig® until 2022.
These two patent grants strengthen and extend the protection for both Oravig® and Sitavig® in the US and Japan respectively while stressing out the innovative nature of the Lauriad® mucoadhesive tablet formulation. Oravig®s patent reinforces and ensures its protection for about ten more years on the US territory while coinciding with the commercial product launch initiated by Vestiq, stated Aude Michel, Head of Corporate Business Development of BioAlliance Pharma. The protection obtained for Sitavig® until 2027 on the Japanese territory should reinforce its attractiveness in our search for commercial partners on an international level.
About BioAlliance Pharma
Dedicated to cancer and supportive care treatment with a focus on resistance targeting and orphan products, BioAlliance conceives and develops innovative products, for specialty markets especially in the hospital setting and for orphan or rare diseases.
Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharmas ambition is to become a leading player in these fields by coupling innovation to patient needs. The companys teams have the key competencies required to identify, develop and register drugs in Europe and the USA.
BioAlliance Pharma has developed an advanced product portfolio:
Loramyc®/Oravig® (oropharyngeal candidiasis in immunocompromised patients): Registered in 26 countries (EU, US, Korea), commercialized in Europe and in the US.
Sitavig® (Acyclovir Lauriad®) (labialis herpes): Registered in the US and in 8 European countries, registration status in the other European countries.
Fentanyl Lauriad® (chronic cancer pain): Positive preliminary Phase I results
Orphan Oncology products
Livatag® (Doxorubicin Transdrug) (primary liver cancer): Phase III on going
Validive® (Clonidine Lauriad®) (mucositis): Phase II on going
AMEP® (invasive melanoma): Phase I on going
For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com
This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2012 Reference Document filed with the AMF on April 18, 2013, which is available on the AMF website (http://www.amf-france.org) or on BioAlliance Pharma SA's website (http://www.bioalliancepharma.com).
BioAlliance Pharma SA
Judith Greciet, CEO
Tel.: +33 1 45 58 76 00
Nicolas Fellmann, CFO
Tel.: +33 1 45 58 71 00
+33 6 64 18 99 59
+33 6 31 13 76 20